Seer, Inc. received a proposal from CEO Omid Farokhzad to acquire shares for $2.45 each, with a Special Committee evaluating the offer.
Quiver AI Summary
Seer, Inc. has received an unsolicited, non-binding acquisition proposal from its CEO, Dr. Omid Farokhzad, to buy all outstanding shares of Class A common stock for $2.45 per share in cash, along with two contingent value rights. In response, Seer's Board of Directors will form a Special Committee of independent directors to assess the proposal and other potential options, ensuring that their actions align with the best interests of the company and its shareholders. The Committee will engage independent financial and legal advisors for support in their evaluation. No action from shareholders is required at this stage, and the details of the proposal will be included in an upcoming Form 8-K filing.
Potential Positives
- The unsolicited acquisition proposal from the CEO indicates confidence in the company's value and potential for investors.
- The formation of a Special Committee to evaluate the proposal demonstrates a structured and responsible approach to corporate governance.
- The retention of independent financial and legal advisors by the Special Committee signifies a commitment to ensure that the best interests of stockholders are prioritized.
Potential Negatives
- The unsolicited acquisition proposal from the CEO may indicate potential instability within the company's leadership and strategy, raising concerns among investors about the company's direction.
- The offer price of $2.45 per share could signal a lack of confidence in the company's current valuation, particularly if this is perceived as too low by shareholders.
- The establishment of a Special Committee to evaluate the proposal suggests that there are significant issues requiring independent review, which may signal underlying challenges faced by the company.
FAQ
What is the recent acquisition proposal from Omid Farokhzad?
Omid Farokhzad proposed to acquire all outstanding shares of Seer’s Class A common stock for $2.45 per share in cash.
How will Seer’s Board of Directors respond to the proposal?
The Board will form a Special Committee of independent directors to evaluate the proposal and other alternatives.
Who is assisting the Special Committee in its evaluation?
The Special Committee will retain independent financial and legal advisors, including Perella Weinberg Partners LP and Wilson Sonsini Goodrich & Rosati.
What should stockholders know at this time regarding the proposal?
No stockholder action is required at this time while the proposal is being evaluated.
What products does Seer, Inc. specialize in?
Seer, Inc. specializes in deep, unbiased proteomics, offering insights through its Proteograph® Product Suite for research use only.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SEER Insider Trading Activity
$SEER insiders have traded $SEER stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $SEER stock by insiders over the last 6 months:
- OMID FAROKHZAD (CEO AND CHAIR) sold 24,385 shares for an estimated $48,645
- DAVID R. HORN (PRESIDENT & CFO) has made 0 purchases and 2 sales selling 15,046 shares for an estimated $27,798.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SEER Hedge Fund Activity
We have seen 15 institutional investors add shares of $SEER stock to their portfolio, and 31 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIREN, L.L.C. removed 1,541,327 shares (-38.5%) from their portfolio in Q1 2026, for an estimated $2,589,429
- FMR LLC removed 703,242 shares (-99.9%) from their portfolio in Q1 2026, for an estimated $1,181,446
- TWO SIGMA INVESTMENTS, LP added 258,951 shares (+102.5%) to their portfolio in Q1 2026, for an estimated $435,037
- RANGELEY CAPITAL, LLC added 164,302 shares (+821.5%) to their portfolio in Q1 2026, for an estimated $276,027
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 150,000 shares (-24.6%) from their portfolio in Q1 2026, for an estimated $252,000
- MILLENNIUM MANAGEMENT LLC removed 116,497 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $195,714
- JACOBS LEVY EQUITY MANAGEMENT, INC added 104,226 shares (+267.1%) to their portfolio in Q1 2026, for an estimated $175,099
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has received an unsolicited, non-binding proposal from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights (the “Proposal”). The full text of the letter received from Farokhzad, M.D., outlining the Proposal will be included on a Form 8-K filing made by Seer.
Seer’s Board of Directors will establish a Special Committee consisting solely of independent directors. The Special Committee will evaluate the Proposal and other alternatives available to Seer, and determine the course of action that it believes is in the best interests of Seer and its stockholders. The Special Committee will retain independent financial and legal advisors to assist it with its work.
No stockholder action is required at this time.
Perella Weinberg Partners LP is serving as financial advisor to Seer and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal counsel.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph ® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
For more information, please email us at [email protected] .
Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the actions to be taken by the Board and the Special Committee. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission and other documents that Seer subsequently files with the Securities and Exchange Commission from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
[email protected]
Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449
Investor Contact:
Marissa Bych
[email protected]
